KR20200026962A - 염증 반응을 포함하는 통증 상태에서 무통증을 위한 말초 제한된 이중 작용성 카파 및 델타 오피오이드 작용제 - Google Patents

염증 반응을 포함하는 통증 상태에서 무통증을 위한 말초 제한된 이중 작용성 카파 및 델타 오피오이드 작용제 Download PDF

Info

Publication number
KR20200026962A
KR20200026962A KR1020207003510A KR20207003510A KR20200026962A KR 20200026962 A KR20200026962 A KR 20200026962A KR 1020207003510 A KR1020207003510 A KR 1020207003510A KR 20207003510 A KR20207003510 A KR 20207003510A KR 20200026962 A KR20200026962 A KR 20200026962A
Authority
KR
South Korea
Prior art keywords
pain
compound
administration
kappa
caused
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020207003510A
Other languages
English (en)
Korean (ko)
Inventor
크레이그 하트릭
Original Assignee
카벤쳐 드러그 디스커버리, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 카벤쳐 드러그 디스커버리, 인크. filed Critical 카벤쳐 드러그 디스커버리, 인크.
Publication of KR20200026962A publication Critical patent/KR20200026962A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Dowels (AREA)
KR1020207003510A 2017-07-06 2018-06-22 염증 반응을 포함하는 통증 상태에서 무통증을 위한 말초 제한된 이중 작용성 카파 및 델타 오피오이드 작용제 Ceased KR20200026962A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762529285P 2017-07-06 2017-07-06
US62/529,285 2017-07-06
PCT/US2018/038936 WO2019010014A1 (en) 2017-07-06 2018-06-22 OPIOID KAPPA AND DELTA AGONIST WITH DOUBLE ACTION LIMITED TO PERIPHERY FOR ANALGESIA IN PAIN CONDITIONS INVOLVING INFLAMMATORY RESPONSE

Publications (1)

Publication Number Publication Date
KR20200026962A true KR20200026962A (ko) 2020-03-11

Family

ID=64950308

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207003510A Ceased KR20200026962A (ko) 2017-07-06 2018-06-22 염증 반응을 포함하는 통증 상태에서 무통증을 위한 말초 제한된 이중 작용성 카파 및 델타 오피오이드 작용제

Country Status (10)

Country Link
US (2) US11185551B2 (enExample)
EP (1) EP3649132B1 (enExample)
JP (1) JP7233741B2 (enExample)
KR (1) KR20200026962A (enExample)
CN (2) CN111278831A (enExample)
AU (1) AU2018297214B2 (enExample)
CA (1) CA3067398A1 (enExample)
IL (1) IL271772A (enExample)
SG (1) SG11201912036XA (enExample)
WO (1) WO2019010014A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3222543A1 (en) * 2021-06-07 2022-12-15 Uwm Research Foundation, Inc. Use of substituted 5-(4-methyl-6-phenyl-4h-benzo[f]imidazo[1,5-a][1,4] diazepin-3-yl)-1,2,4-oxadiazoles in the treatment of inflammatory conditions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2180852C2 (ru) 1994-12-12 2002-03-27 Омерос Медикл Системс, Инк. Ингибирующий раствор и способ подавления боли, воспаления или спазма
US20030008807A1 (en) * 2001-06-14 2003-01-09 The Regents Of The University Of California Novel signaling pathway for the production of inflammatory pain and neuropathy
US20050152905A1 (en) * 2002-08-22 2005-07-14 Omoigui Osemwota S. Method of biochemical treatment of persistent pain
WO2015114660A1 (en) 2014-01-24 2015-08-06 Cadila Healtchare Limited Novel heterobicyclic compounds as kappa opioid agonists

Also Published As

Publication number Publication date
JP7233741B2 (ja) 2023-03-07
EP3649132B1 (en) 2023-12-27
CN111278831A (zh) 2020-06-12
SG11201912036XA (en) 2020-01-30
EP3649132A1 (en) 2020-05-13
US20210161912A1 (en) 2021-06-03
AU2018297214A1 (en) 2020-01-16
EP3649132A4 (en) 2021-04-07
US20220288089A1 (en) 2022-09-15
IL271772A (en) 2020-02-27
AU2018297214B2 (en) 2022-09-01
WO2019010014A1 (en) 2019-01-10
JP2020525548A (ja) 2020-08-27
CN116440140A (zh) 2023-07-18
US11185551B2 (en) 2021-11-30
CA3067398A1 (en) 2019-01-10

Similar Documents

Publication Publication Date Title
Sikiric et al. Brain-gut axis and pentadecapeptide BPC 157: Theoretical and practical implications
Eidson et al. Inflammatory mediators of opioid tolerance: implications for dependency and addiction
Sanger et al. Treatment of nausea and vomiting: gaps in our knowledge
Kanoski et al. The role of nausea in food intake and body weight suppression by peripheral GLP-1 receptor agonists, exendin-4 and liraglutide
Rudd et al. Anti-emetic activity of ghrelin in ferrets exposed to the cytotoxic anti-cancer agent cisplatin
JP4817495B2 (ja) 外因性カンナビノイドでの痛みの制御
US20170042878A1 (en) Compositions comprising scopolamine and ketamine in the treatment of depression
Sun et al. Lappaconitine, a C18-diterpenoid alkaloid, exhibits antihypersensitivity in chronic pain through stimulation of spinal dynorphin A expression
EP2311446A1 (en) Compositions comprising Tramadol and Celecoxib in the treatment of pain
Rastogi et al. Novel treatment modalities for painful diabetic neuropathy
US20250241996A1 (en) Combinatorial, and rotational combinatorial therapies
CN111902140A (zh) 用于预防或治疗瘙痒的含有作为活性成分的hdac6抑制剂的药物组合物
Bischoff et al. The oral efficacy of vardenafil hydrochloride for inducing penile erection in a conscious rabbit model
Kim et al. Anti-nociceptive effects of dual neuropeptide antagonist therapy in mouse model of neuropathic and inflammatory pain
WO2016042501A1 (en) Trpa1 antagonist for the treatment of pain associated to diabetic neuropathic pain
Folkesson et al. Low dose of donepezil improves gabapentin analgesia in the rat spared nerve injury model of neuropathic pain: single and multiple dosing studies
US20220288089A1 (en) Peripherally-restricted dual-acting kappa and delta opioid agonist for analgesia in pain states involving the inflammatory response
JP2009534360A (ja) アルファ−ケトグルタレートを含む組成物およびその筋性能を調節するための使用
US12377111B2 (en) Composition, comprising thiamine derivative, for prevention or treatment of hypercortisolemia
US20060084659A1 (en) Augmentation of psychotherapy with cannabinoid reuptake inhibitors
Taheri et al. Comparing the use of memantine with dextromethorphan and placebo to reduce pain before orthopedic surgery
CN112972440B (zh) 麝香酮在制备防治抑郁症的药物中的用途
WO2017180064A1 (en) A drug for the effective control of acute and/or chronic pain and a method for its administration
Chen et al. Effect of excitatory amino acid receptor agonists on penile erection after administration into paraventricular nucleus of hypothalamus in the rat
RU2797615C2 (ru) Способы применения феноксипропиламинового соединения для лечения боли

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200205

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210616

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230528

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20230828

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20230528

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I